Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis
- 1 December 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 8 (12) , 1632-1641
Abstract
Combination therapy with infliximab and azathioprine has been shown to be superior to either treatment alone in Crohn's disease (CD). However, the benefit of combining adalimumab with an immunomodulator remains controversial. The aim of this study was to compare the efficacy of adalimumab monotherapy with combination therapy for induction and maintenance of response and remission in CD using a meta-analysis of the current literature. We performed a systematic literature search using Medline, Embase, Cochrane and several other databases. Prospective randomized controlled trials, retrospective cohort and case-controlled studies were included. The primary outcomes included induction of response and remission (up to week 12), maintenance of clinical response and remission (1 year) and the need for dose escalation. Several subgroup and sensitivity analyses were performed. Eighteen out of 2743 retrieved studies were included. A meta-analysis of 7 studies assessing induction of remission (n=1984) showed that ADA monotherapy was inferior to combination therapy [OR=0.78 (0.64-0.96), p=0.02]. A meta-analysis of 4 studies revealed that combination therapy was not statistically different from ADA for maintenance of remission [OR=1.08 (0.79-1.48), p=0.48]. Combination therapy was also not different from ADA monotherapy in terms of requirement for dose escalation [OR=1.13 (0.69-1.85), p=0.62]. Combination therapy with ADA and immunomodulator was mildly superior to ADA monotherapy for induction of remission in CD. The rate of remission at 1 year and the need for dose escalation were similar in both groups. These findings should be interpreted with caution in view of possible confounders and should be further validated by randomized controlled trials.Keywords
This publication has 47 references indexed in Scilit:
- Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assayJournal of Pharmaceutical and Biomedical Analysis, 2013
- TNF inhibitor therapy for rheumatoid arthritisBiomedical Reports, 2012
- Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in JapanClinical Rheumatology, 2012
- Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: Results from CAREInflammatory Bowel Diseases, 2012
- Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patientsAlimentary Pharmacology & Therapeutics, 2011
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trialGut, 2007
- Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s diseaseGut, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007